482 related articles for article (PubMed ID: 25178252)
1. Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications.
Trujillo T; Dobesh PP
Drugs; 2014 Sep; 74(14):1587-603. PubMed ID: 25178252
[TBL] [Abstract][Full Text] [Related]
2. A clinical and pharmacologic assessment of once-daily versus twice-daily dosing for rivaroxaban.
Kreutz R
J Thromb Thrombolysis; 2014; 38(2):137-49. PubMed ID: 24293106
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic and pharmacokinetic basics of rivaroxaban.
Kreutz R
Fundam Clin Pharmacol; 2012 Feb; 26(1):27-32. PubMed ID: 21848931
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.
Mueck W; Lensing AW; Agnelli G; Decousus H; Prandoni P; Misselwitz F
Clin Pharmacokinet; 2011 Oct; 50(10):675-86. PubMed ID: 21895039
[TBL] [Abstract][Full Text] [Related]
5. Rivaroxaban: an oral factor Xa inhibitor.
Thomas TF; Ganetsky V; Spinler SA
Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.
Mueck W; Eriksson BI; Bauer KA; Borris L; Dahl OE; Fisher WD; Gent M; Haas S; Huisman MV; Kakkar AK; Kälebo P; Kwong LM; Misselwitz F; Turpie AG
Clin Pharmacokinet; 2008; 47(3):203-16. PubMed ID: 18307374
[TBL] [Abstract][Full Text] [Related]
7. The new oral anticoagulants in atrial fibrillation: once daily or twice daily?
Renda G; De Caterina R
Vascul Pharmacol; 2013; 59(3-4):53-62. PubMed ID: 23872195
[TBL] [Abstract][Full Text] [Related]
8. Dose-finding study of rivaroxaban in hemodialysis patients.
De Vriese AS; Caluwé R; Bailleul E; De Bacquer D; Borrey D; Van Vlem B; Vandecasteele SJ; Emmerechts J
Am J Kidney Dis; 2015 Jul; 66(1):91-8. PubMed ID: 25804678
[TBL] [Abstract][Full Text] [Related]
9. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Graff J; Harder S
Clin Pharmacokinet; 2013 Apr; 52(4):243-54. PubMed ID: 23389892
[TBL] [Abstract][Full Text] [Related]
10. Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
Turpie AG; Kreutz R; Llau J; Norrving B; Haas S
Thromb Haemost; 2012 Nov; 108(5):876-86. PubMed ID: 23014816
[TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.
Burness CB; Perry CM
Drugs; 2014 Feb; 74(2):243-62. PubMed ID: 24430916
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Mueck W; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Kälebo P; Muelhofer E; Misselwitz F; Eriksson BI
Thromb Haemost; 2008 Sep; 100(3):453-61. PubMed ID: 18766262
[TBL] [Abstract][Full Text] [Related]
13. Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications.
Kubitza D; Berkowitz SD; Misselwitz F
Clin Appl Thromb Hemost; 2016 Jul; 22(5):412-22. PubMed ID: 26893445
[TBL] [Abstract][Full Text] [Related]
14. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
Morell J; Sullivan B; Khalabuda M; McBride BF
J Clin Pharmacol; 2010 Sep; 50(9):986-1000. PubMed ID: 20124518
[TBL] [Abstract][Full Text] [Related]
15. Rivaroxaban -- an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme.
Haas S
Eur J Haematol; 2009 May; 82(5):339-49. PubMed ID: 19187276
[TBL] [Abstract][Full Text] [Related]
16. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
Reddy P; Giugliano RP
J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor.
Kreutz R
Curr Clin Pharmacol; 2014 Feb; 9(1):75-83. PubMed ID: 24218999
[TBL] [Abstract][Full Text] [Related]
18. Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders.
Perzborn E; Kubitza D; Misselwitz F
Hamostaseologie; 2007 Sep; 27(4):282-9. PubMed ID: 17938768
[TBL] [Abstract][Full Text] [Related]
19. New anticoagulants: moving on from scientific results to clinical implementation.
Eerenberg ES; van Es J; Sijpkens MK; Büller HR; Kamphuisen PW
Ann Med; 2011 Dec; 43(8):606-16. PubMed ID: 21864021
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF.
Girgis IG; Patel MR; Peters GR; Moore KT; Mahaffey KW; Nessel CC; Halperin JL; Califf RM; Fox KA; Becker RC
J Clin Pharmacol; 2014 Aug; 54(8):917-27. PubMed ID: 24668660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]